These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 29745903)

  • 1. System-based strategies for p53 recovery.
    Azam MR; Fazal S; Ullah M; Bhatti AI
    IET Syst Biol; 2018 Jun; 12(3):101-107. PubMed ID: 29745903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On p53 revival using system oriented drug dosage design.
    Haseeb M; Azam S; Bhatti AI; Azam R; Ullah M; Fazal S
    J Theor Biol; 2017 Feb; 415():53-57. PubMed ID: 27979498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic behavior of the p53-Mdm2 core module under the action of drug Nutlin and dual delays.
    Yang J; Yan F; Liu H
    Math Biosci Eng; 2021 Apr; 18(4):3448-3468. PubMed ID: 34198395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attractor landscape analysis reveals feedback loops in the p53 network that control the cellular response to DNA damage.
    Choi M; Shi J; Jung SH; Chen X; Cho KH
    Sci Signal; 2012 Nov; 5(251):ra83. PubMed ID: 23169817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
    Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
    J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway.
    Zauli G; Voltan R; Bosco R; Melloni E; Marmiroli S; Rigolin GM; Cuneo A; Secchiero P
    Clin Cancer Res; 2011 Feb; 17(4):762-70. PubMed ID: 21106726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells.
    Secchiero P; Zerbinati C; di Iasio MG; Melloni E; Tiribelli M; Grill V; Zauli G
    Curr Drug Metab; 2007 May; 8(4):395-403. PubMed ID: 17504227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.
    Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
    Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticancer effects of the p53 activator nutlin-3 in Ewing's sarcoma cells.
    Sonnemann J; Palani CD; Wittig S; Becker S; Eichhorn F; Voigt A; Beck JF
    Eur J Cancer; 2011 Jun; 47(9):1432-41. PubMed ID: 21334198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Model-based investigation of the transcriptional activity of p53 and its feedback loop regulation via 14-3-3σ.
    Vera J; Nikolov S; Lai X; Singh A; Wolkenhauer O
    IET Syst Biol; 2011 Sep; 5(5):293-307. PubMed ID: 22010756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic Behavior of p53 Driven by Delay and a Microrna-34a-Mediated Feedback Loop.
    Gao C; Liu H; Yan F
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32070036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERK1/2 activation mediated by the nutlin‑3‑induced mitochondrial translocation of p53.
    Lee SY; Shin SJ; Kim HS
    Int J Oncol; 2013 Mar; 42(3):1027-35. PubMed ID: 23314357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status.
    Zauli G; Celeghini C; Melloni E; Voltan R; Ongari M; Tiribelli M; di Iasio MG; Lanza F; Secchiero P
    Haematologica; 2012 Nov; 97(11):1722-30. PubMed ID: 22689683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma.
    de Lange J; Ly LV; Lodder K; Verlaan-de Vries M; Teunisse AF; Jager MJ; Jochemsen AG
    Oncogene; 2012 Mar; 31(9):1105-16. PubMed ID: 21765463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
    Drakos E; Singh RR; Rassidakis GZ; Schlette E; Li J; Claret FX; Ford RJ; Vega F; Medeiros LJ
    Leukemia; 2011 May; 25(5):856-67. PubMed ID: 21394100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticles loaded with Nutlin-3 display cytotoxicity towards p53(wild-type) JVM-2 but not towards p53(mutated) BJAB leukemic cells.
    Voltan R; Secchiero P; Ruozi B; Caruso L; Forni F; Palomba M; Zauli G; Vandelli MA
    Curr Med Chem; 2013; 20(21):2712-22. PubMed ID: 23627936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamics of p53 and Wnt cross talk.
    Zubbair Malik M; Ali S; Alam MJ; Ishrat R; Brojen Singh RK
    Comput Biol Chem; 2015 Dec; 59 Pt B():55-66. PubMed ID: 26375870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.
    Michaelis M; Rothweiler F; Barth S; Cinatl J; van Rikxoort M; Löschmann N; Voges Y; Breitling R; von Deimling A; Rödel F; Weber K; Fehse B; Mack E; Stiewe T; Doerr HW; Speidel D; Cinatl J
    Cell Death Dis; 2011 Dec; 2(12):e243. PubMed ID: 22170099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
    Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in the therapeutic perspectives of Nutlin-3.
    Secchiero P; Bosco R; Celeghini C; Zauli G
    Curr Pharm Des; 2011; 17(6):569-77. PubMed ID: 21391907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.